Alimera Sciences (ALIM) 10-Q 9 May 18 2018 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 07, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	ALIMERA SCIENCES INC
Entity Central Index Key	1,267,602
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Amendment Flag	false
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		70,038,411

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 20,253,000	$ 24,067,000
Restricted cash	35,000	34,000
Accounts receivable, net	12,354,000	11,435,000
Prepaid expenses and other current assets	1,992,000	2,278,000
Inventory (Note 6)	1,224,000	1,508,000
Total current assets	35,858,000	39,322,000
NON-CURRENT ASSETS:
Property and equipment, net	1,531,000	1,410,000
Intangible asset, net (Note 7)	18,185,000	18,664,000
Deferred tax asset	543,000	528,000
TOTAL ASSETS	56,117,000	59,924,000
CURRENT LIABILITIES:
Accounts payable	4,969,000	5,905,000
Accrued expenses (Note 8)	2,280,000	3,582,000
Capital lease obligations	216,000	184,000
Total current liabilities	7,465,000	9,671,000
NON-CURRENT LIABILITIES:
Note payable (Note 10)	37,254,000	34,365,000
Capital lease obligations — less current portion	283,000	203,000
Other non-current liabilities	2,564,000	766,000
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS’ EQUITY:
Preferred stock
Common stock, $.01 par value — 150,000,000 shares authorized, 69,987,229 shares issued and outstanding at March 31, 2018 and 69,146,381 shares issued and outstanding at December 31, 2017	700,000	691,000
Additional paid-in capital	342,822,000	341,622,000
Common stock warrants	3,707,000	3,707,000
Accumulated deficit	(406,758,000)	(399,075,000)
Accumulated other comprehensive loss	(715,000)	(821,000)
TOTAL STOCKHOLDERS’ EQUITY	8,551,000	14,919,000
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	56,117,000	59,924,000
Series A convertible preferred stock
STOCKHOLDERS’ EQUITY:
Preferred stock	19,227,000	19,227,000
Series B convertible preferred stock
STOCKHOLDERS’ EQUITY:
Preferred stock	$ 49,568,000	$ 49,568,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized	10,000,000	10,000,000
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	69,987,229	69,146,381
Common stock, shares outstanding	69,987,229	69,146,381
Series A convertible preferred stock
Preferred stock, shares authorized	1,300,000	1,300,000
Preferred stock, shares issued	600,000	600,000
Preferred stock, shares outstanding	600,000	600,000
Preferred stock, liquidation preference	$ 24,000,000	$ 24,000,000
Series B convertible preferred stock
Preferred stock, shares authorized	8,417	8,417
Preferred stock, shares issued	8,416.251	8,416.251
Preferred stock, shares outstanding	8,416.251	8,416.251
Preferred stock, liquidation preference	$ 50,750,000	$ 50,750,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Statement [Abstract]
NET REVENUE	$ 9,802	$ 6,618
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(1,276)	(587)
GROSS PROFIT	8,526	6,031
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	2,822	2,110
GENERAL AND ADMINISTRATIVE EXPENSES	3,855	3,264
SALES AND MARKETING EXPENSES	5,969	5,502
DEPRECIATION AND AMORTIZATION	649	666
OPERATING EXPENSES	13,295	11,542
SEGMENT LOSS FROM OPERATIONS	(4,769)	(5,511)
INTEREST EXPENSE AND OTHER	(1,151)	(1,337)
UNREALIZED FOREIGN CURRENCY GAIN (LOSS), NET	2	(28)
CHANGE IN FAIR VALUE OF DERIVATIVE WARRANT LIABILITY	0	167
LOSS ON EARLY EXTINGUISHMENT OF DEBT	(1,766)	0
NET LOSS BEFORE TAXES	(7,684)	(6,709)
PROVISION FOR TAXES	0	(26)
NET LOSS	$ (7,684)	$ (6,735)
NET LOSS PER SHARE — Basic and diluted (in USD per share)	$ (0.11)	$ (0.10)
WEIGHTED AVERAGE SHARES OUTSTANDING — Basic and diluted (in shares)	69,883,012	64,862,904

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Statement of Comprehensive Income [Abstract]
NET LOSS	$ (7,684)	$ (6,735)
OTHER COMPREHENSIVE INCOME
Foreign currency translation adjustments	106	49
TOTAL OTHER COMPREHENSIVE INCOME	106	49
COMPREHENSIVE LOSS	$ (7,578)	$ (6,686)

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (7,684,000)	$ (6,735,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	649,000	666,000
Inventory reserve	0	8,000
Unrealized foreign currency transaction loss (gain)	(2,000)	28,000
Loss on early extinguishment of debt	1,766,000	0
Amortization of debt discount	214,000	343,000
Stock-based compensation expense	1,207,000	1,166,000
Change in fair value of derivative warrant liability	0	(167,000)
Changes in assets and liabilities:
Accounts receivable	(867,000)	3,090,000
Prepaid expenses and other current assets	309,000	8,000
Inventory	299,000	(361,000)
Accounts payable	(992,000)	(1,053,000)
Accrued expenses and other current liabilities	70,000	(1,147,000)
Other long-term liabilities	(17,000)	(15,000)
Net cash used in operating activities	(5,048,000)	(4,169,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(91,000)	(57,000)
Net cash used in investing activities	(91,000)	(57,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercise of stock options	2,000	0
Issuance of debt	40,000,000	0
Payment of principal on notes payable	(35,000,000)	0
Payment of extinguishment of debt costs	(2,544,000)	0
Payment of deferred financing costs	(1,142,000)	0
Payment of capital lease obligations	(83,000)	(38,000)
Net cash provided by (used in) financing activities	1,233,000	(38,000)
EFFECT OF EXCHANGE RATES ON CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	93,000	22,000
NET DECREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	(3,813,000)	(4,242,000)
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — Beginning of period	24,101,000	31,010,000
CASH AND CASH EQUIVALENTS AND RESTRICTED CASH — End of period	20,288,000	26,768,000
SUPPLEMENTAL DISCLOSURES:
Cash paid for interest	932,000	985,000
Cash paid for income taxes	0	11,000
Supplemental schedule of non-cash investing and financing activities:
Property and equipment acquired under capital leases	252,000	0
Note payable end of term payment accrued but unpaid	1,800,000	1,400,000
Payments of dividends	$ 0	$ 0

Nature of Operations

Nature of Operations	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations	NATURE OF OPERATIONS Alimera Sciences, Inc., together with its wholly-owned subsidiaries (the Company), is a pharmaceutical company that specializes in the commercialization and development of ophthalmic pharmaceuticals. The Company was formed on June 4, 2003 under the laws of the State of Delaware. The Company is presently focused on diseases affecting the back of the eye, or retina, because the Company’s management believes these diseases are not well treated with current therapies and represent a significant market opportunity. The Company’s only commercial product is ILUVIEN ® , which has received marketing authorization in the United States (U.S.), Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the United Kingdom. In the U.S., ILUVIEN is indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). In the European Economic Area (EEA) countries in which ILUVIEN has received marketing authorization, it is indicated for the treatment of vision impairment associated with DME considered insufficiently responsive to available therapies. As part of the approval process in Europe, the Company committed to conduct a five -year, post-authorization, open label registry study in 800 patients treated with ILUVIEN. Due to its post market safety surveillance not showing any unexpected safety signals the Company requested and received approval to modify its protocol to cap enrollment in the study. As of March 31, 2018, 562 patients were enrolled in this study. The Company commercially markets ILUVIEN in the U.S., Germany, the United Kingdom, Portugal, Austria and Ireland. The Company began selling ILUVIEN in Austria in the first quarter of 2017 and in Ireland in the fourth quarter of 2017. In addition, the Company has entered into various agreements under which distributors will provide regulatory, reimbursement or sales and marketing support for future commercialization of ILUVIEN in several countries in the Middle East, as well as France, Italy, Spain, Australia, New Zealand and Canada. In the third quarter of 2016, the Company’s Middle East distributor launched ILUVIEN and initiated named patient sales in the United Arab Emirates. The Company’s Italian distributor launched ILUVIEN in Italy in the second quarter of 2017. As of March 31, 2018, the Company has recognized sales of ILUVIEN to the Company’s distributors in the Middle East, Italy and Spain. In July 2017, the Company amended its license with EyePoint Pharmaceuticals US, Inc. (EyePoint) formerly known as pSivida US, Inc. for the technology underlying ILUVIEN to include the treatment of uveitis, including non-infectious posterior uveitis (NIPU) in Europe, the Middle East and Africa (Note 9). Uveitis is an inflammatory disease of the uveal tract, which is comprised of the iris, ciliary body and choroid, that can lead to severe vision loss and blindness. In December 2017, the Company filed an application for a new indication for ILUVIEN for NIPU in the 17 EEA countries where ILUVIEN is currently approved for the treatment of DME. The regulatory authorities requested additional follow-up data from the clinical trials to support the application. The Company plans to submit the the follow-up data by the end of 2018, when it is expected to be available. The Company expects that it will obtain approval of its application for NIPU in the first half of 2019.

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	BASIS OF PRESENTATION The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information, the instructions to Form 10-Q and Article 10-01 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying interim financial statements and related notes should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2017 and related notes included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 2, 2018. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Except for the newly adopted accounting standards noted below, the accounting policies followed for quarterly financial reporting are the same as those disclosed in the Notes to Financial Statements included in the Company’s Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2017. Research and Development Expenses Research and development expenses were $104,000 and $350,000 for the three months ended March 31, 2018 and 2017, respectively. Recent Accounting Pronouncements From time to time, the Financial Accounting Standards Board (FASB) or other standard setting bodies issue new accounting pronouncements that we adopt as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. Adoption of New Accounting Standards In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) , which amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB has subsequently issued an additional, clarifying ASU to address issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard became effective for interim and annual periods beginning on January 1, 2018. The new standard is required to be adopted using either a full-retrospective or a modified-retrospective approach. The Company adopted the new revenue guidance on January 1, 2018 using the modified-retrospective approach. The Company elected the practical expedient to apply the new revenue standard only to contracts that were not completed as of January 1, 2018. The most significant impact of the new revenue standard relates to the accounting for the Company’s variable consideration and consideration payable to customers, specifically dealing with costs paid to its distributors. The new revenue standard requires the Company to classify consideration payable to customers as cost of goods sold, excluding depreciation and amortization, which consideration was previously classified as a discount to net revenue. Adoption did not have a material impact on the Company’s financial statements on an ongoing basis. See Note 4 for expanded disclosures. In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230) . ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. The standard is effective for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash . ASU 2016-18 requires a statement of cash flows to explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements. The Company’s condensed consolidated statement of cash flows for the three months ended March 31, 2017 has been reclassified for this ASU. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope Modification Accounting . The new standard clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. This standard became effective January 1, 2018. The adoption of this guidance did not have a material impact on the Company’s financial statements. Accounting Standards Issued but Not Yet Effective In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) . This standard requires all leases with durations greater than twelve months to be recognized on the balance sheet and is effective for interim and annual reporting periods beginning after December 15, 2018, although early adoption is permitted. The primary effect of adoption will be the requirement to record right-of-use assets and corresponding lease obligations for current operating leases. In addition, the standard will require that we update our systems, processes and controls we use to track, record and account for our lease portfolio. The Company is currently in the process of evaluating the impact of the adoption on the Company’s financial statements. In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income , to allow reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Upon adoption of the ASU, entities will be required to describe the accounting policy for releasing income tax effects from accumulated other comprehensive income. The standard is required to be adopted for periods beginning after December 15, 2018, with early adoption available. The Company is currently in the process of evaluating the impact of the adoption on the Company’s financial statements.

Revenue Recognition

Revenue Recognition	3 Months Ended
	Mar. 31, 2018
Revenue from Contract with Customer [Abstract]
Revenue Recognition	REVENUE RECOGNITION Net Revenue The Company sells its products to major pharmaceutical distributors, pharmacies and doctors (collectively, its “Customers”). In addition to distribution agreements with Customers, the Company enters into arrangements with healthcare providers and payors that provide for government-mandated and/or privately-negotiated rebates, chargebacks, and discounts with respect to the purchase of the Company’s products. All of our current contracts have a single performance obligation as the promise to transfer the individual goods is not separately identifiable from other promises in the contracts and, is therefore, not distinct. Currently, all of our revenue is derived from product sales. The Company recognizes revenues from product sales at a point in time when the Customer obtains control, typically upon delivery. The Company accrues for fulfillment costs when the related revenue is recognized. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. Estimates of Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for reserves related to statutory rebates to State Medicaid and other government agencies; commercial rebates and fees to Managed Care Organizations (MCOs), Group Purchasing Organizations (GPOs), distributors, and specialty pharmacies; product returns; sales discounts (including trade discounts); distributor costs; wholesaler chargebacks; and allowances for patient assistance programs relating to the Company’s sales of its products. These reserves are based on estimates of the amounts earned or to be claimed on the related sales. Management’s estimates take into consideration historical experience, current contractual and statutory requirements, specific known market events and trends, industry data, and Customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. The amount of variable consideration included in the net sales price is limited to the amount that is probable not to result in a significant reversal in the amount of the cumulative revenue recognized in a future period. If actual results vary, the Company may adjust these estimates, which could have an effect on earnings in the period of adjustment. Consideration Payable to Customers Distribution service fees are payments issued to distributors for compliance with various contractually-defined inventory management practices or services provided to support patient access to a product. These fees are generally based on a set fee per unit of gross purchases but can also be based on additional services these entities provide. Most of these costs are reflected under the new guidance as a cost of sale; however, to the extent the benefit from services can be separately identified and the fair value determined, costs are classified as Selling, general and administrative expenses. Distribution service fees reserves are based on the terms of each individual contract and are classified within accrued expenses. Product Returns The Company’s policies provide for product returns in the following circumstances: (a) expiration of shelf life on certain products; (b) product damaged while in the Customer’s possession; and (c) following product recalls. Generally, returns for expired product are accepted three months before and up to one year after the expiration date of the related product, and the related product is destroyed after it is returned. The Company may either refund the sales price paid by the Customer by issuance of a credit, or exchange the returned product with replacement inventory. The Company typically does not provide cash refunds. The Company estimates the proportion of recorded revenue that will result in a return by considering relevant factors, including but not limited to: • historical returns experience; • the estimated level of inventory in the distribution channel; • the shelf life of products; and • product recalls, if any. The estimation process for product returns involves, in each case, a number of interrelating assumptions, which vary for each Customer. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue from Product sales in the period the related revenue is recognized, and because this returned product cannot be resold, there is no corresponding asset for product returns. To date, product returns have been minimal. Other Revenue The Company enters into agreements in which it licenses certain rights to its products to partner companies that act as distributors. The terms of these arrangements typically include payment to the Company of one or more of the following: non-refundable, up-front license fees; development, regulatory and commercial milestone payments; payments for manufacturing supply services the Company provides; and a revenue share on net sales of licensed products. Each of these payments is recognized as other revenues. As part of the accounting for these arrangements, the Company must develop estimates that require judgment to determine the stand-alone selling price for each performance obligation identified in the contract. Performance obligations are promises in a contract to transfer a distinct good or service to the Customer, and the Company recognizes revenue when, or as performance obligations are satisfied. The Company uses key assumptions to determine the stand-alone selling price; these assumptions may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical, regulatory and commercial success. Certain of these agreements include consideration in the form of milestone payments. At the inception of each arrangement that includes milestone payments, the Company evaluates the recognition of milestone payments. Typically, milestone payments are associated with events that are not entirely within the control of the Company or the licensee, such as regulatory approvals; are included in the transaction price; and are subject to a constraint until it is probable that there will not be a significant revenue reversal, typically upon achievement of the milestone. At the end of each reporting period, the Company re-evaluates the probability of achievement of such milestones and any related constraint, and if necessary, adjusts its estimate of the overall transaction price. Customer Payment Obligations The Company receives payments from its Customers based on billing schedules established in each contract, which vary across the Company’s locations, but generally range between 30 to 120 days. Occasionally, the timing of receipt of payment for the Company’s international Customers can be extended. Amounts are recorded as accounts receivable when the Company’s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation is that Customer will pay for the product or services in one year or less of receiving those products or services. The income statement reclassifications that occurred under the new guidance for the three months ended March 31, 2018 are summarized as follows: Three Months Ended March 31, 2018 Under previous revenue recognition guidance Reclassification As reported (in thousands) NET REVENUE $ 9,630 $ 172 $ 9,802 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (1,104 ) (172 ) (1,276 ) GROSS PROFIT $ 8,526 $ — $ 8,526

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Going Concern	GOING CONCERN The accompanying Interim Financial Statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Interim Financial Statements do not include any adjustments that might result from the outcome of this uncertainty. To date, the Company has incurred recurring losses and negative cash flow from operations and has accumulated a deficit of $406,758,000 from inception through March 31, 2018 . As of March 31, 2018 , the Company had approximately $20,253,000 in cash and cash equivalents. The Company’s ability to achieve profitability and positive cash flow depends upon its ability to increase revenue and contain its expenses. Further, the Company must maintain compliance with the debt covenants of its $40,000,000 Loan and Security Agreement (2018 Loan Agreement) with Solar Capital Ltd. (Solar Capital) as Collateral Agent (Agent), and the parties signing the 2018 Loan Agreement from time to time as Lenders, including Solar Capital in its capacity as a Lender (each a Lender and collectively, the Lenders) (see Note 10). In management’s opinion, the uncertainty regarding future revenues raises substantial doubt about the Company’s ability to continue as a going concern without access to additional debt or equity financing, over the course of the next twelve months. In particular, the Company must maintain compliance with the covenants of the 2018 Loan Agreement (see Note 10). To meet the Company’s future working capital needs, the Company may need to raise additional debt or equity financing. The Company may be able to access capital under the Company’s current at-the-market offering facility, which has $25,000,000 of remaining availability (see Note 13). While the Company has historically been able to raise additional capital through issuance of equity and/or debt financing, and while the Company has implemented a plan to control its expenses to satisfy its obligations due within one year from the date of issuance of these financial statements, the Company cannot guarantee that it will be able to maintain debt compliance, raise additional equity or increase revenue. Accordingly, there is substantial doubt about the Company’s ability to continue as a going concern within one year after these financial statements are issued.

Inventory

Inventory	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Inventory	INVENTORY Inventory consisted of the following: March 31, 2018 December 31, 2017 (In thousands) Component parts (1) $ 371 $ 404 Work-in-process (2) 290 587 Finished goods 563 517 Total inventory $ 1,224 $ 1,508 (1) Component parts inventory consists of manufactured components of the ILUVIEN applicator. (2) Work-in-process primarily consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by regulatory authorities in Europe and the U.S.

Intangible Asset

Intangible Asset	3 Months Ended
	Mar. 31, 2018
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Intangible Asset	INTANGIBLE ASSET As a result of the approval of ILUVIEN by the U.S. Food and Drug Administration (FDA) in September 2014, the Company was required to pay EyePoint a milestone payment of $25,000,000 (the EyePoint Milestone Payment) in October 2014 (see Note 9). The gross carrying amount of the intangible asset was $25,000,000 , which is being amortized over approximately 13 years from the payment date. The amortization expense related to the intangible asset was approximately $478,000 for both the three months ended March 31, 2018 and 2017, respectively. The net book value of the intangible asset was $18,185,000 and $18,664,000 as of March 31, 2018 and December 31, 2017, respectively. The estimated future amortization expense as of March 31, 2018 for the remaining periods in the next five years and thereafter is as follows: Years Ending December 31 (In thousands) 2018 $ 1,462 2019 1,940 2020 1,946 2021 1,940 2022 1,940 Thereafter 8,957 Total $ 18,185

Accrued Expenses

Accrued Expenses	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Accrued Expenses	ACCRUED EXPENSES Accrued expenses consisted of the following: March 31, 2018 December 31, 2017 (In thousands) Accrued clinical investigator expenses $ 661 $ 696 Accrued compensation expenses 506 511 Accrued rebate, chargeback and other revenue reserves 464 305 Accrued End of Term Payment (see Note 10) — 1,400 Other accrued expenses 649 670 Total accrued expenses $ 2,280 $ 3,582

License Agreements

License Agreements	3 Months Ended
	Mar. 31, 2018
Organization, Consolidation and Presentation of Financial Statements [Abstract]
License agreements	LICENSE AGREEMENTS EyePoint Agreement The Company entered into an agreement with EyePoint for the use of fluocinolone acetonide (FAc) in EyePoint’s proprietary insert technology in February 2005. This agreement was subsequently amended a number of times (as amended, the EyePoint Agreement). The EyePoint Agreement provides the Company with a worldwide exclusive license to utilize certain underlying technology used in the development and commercialization of ILUVIEN. 2008 Amended and Restated Collaboration Agreement Pursuant to the payment terms of the 2008 Amended and Restated Agreement (the 2008 Agreement), the Company was required to share with EyePoint 20% of the net profits of ILUVIEN, determined on a cash basis and 33% of any lump sum milestone payments received from a sub-licensee of ILUVIEN. In connection with this arrangement, the Company was entitled to recover out of EyePoint’s share of the net profits of ILUVIEN, 20% of ILUVIEN’s commercialization costs (as defined in the EyePoint Agreement) that were incurred prior to product profitability. (The Company’s future rights to recover these amounts from EyePoint are referred to as the Future Offset.) In connection with the New Collaboration Agreement discussed below, the Future Offset was further amended. New Collaboration Agreement - Second Amended and Restated Collaboration Agreement On July 10, 2017, the Company and EyePoint entered into a Second Amended and Restated Collaboration Agreement (the New Collaboration Agreement), which amends and restates the EyePoint Agreement. Prior to entering into the New Collaboration Agreement, the Company held the worldwide license from EyePoint for the use of EyePoint’s proprietary insert technology for the treatment of all ocular diseases other than uveitis. The New Collaboration Agreement expands the license to include uveitis, including NIPU, in Europe, the Middle East and Africa and allows the Company to also pursue an indication for posterior uveitis for ILUVIEN in those territories. The New Collaboration Agreement converts the Company’s obligation to share 20% of its net profits to a royalty payable on global net revenues of ILUVIEN. The Company began paying a 2% royalty on net revenues and other related consideration to EyePoint on July 1, 2017. This royalty amount will increase to 6% upon the earlier of December 12, 2018 or the receipt of the first marketing approval for ILUVIEN for the treatment of NIPU. The Company will pay an additional 2% royalty on global net revenues and other related consideration in excess of $75,000,000 in any year. During the three months ended March 31, 2018, the Company recognized approximately $193,000 of royalty expense, which is included in cost of goods sold, excluding depreciation and amortization. As of March 31, 2018, approximately $193,000 of this royalty expense was included in the Company’s accounts payable. During the three months ended March 31, 2017, the Company recognized approximately $197,000 of profit share expense. In connection with the New Collaboration Agreement, the Company and EyePoint first agreed to cap the Future Offset amount at $25,000,000 as of June 30, 2017 and the Company then agreed to forgive $10,000,000 of the total $25,000,000 of the Future Offset at the July 10, 2017 amendment date. Following the signing of the New Collaboration Agreement, the Company retains a right to recover up to the remaining $15,000,000 of the Future Offset. The Company is entitled to recover up to $15,000,000 as a reduction of future royalties otherwise owed to EyePoint as follows: • In the first two years following the increase in royalty amount to 6% , the royalty will be reduced to 4% for net revenues and other related consideration up to $75,000,000 annually and 5% for net revenues and other related consideration in excess of $75,000,000 on an annual basis; and • Beginning with the third year following the increase in royalty amount to 6% , the royalty will be reduced to approximately 5.2% for net revenues and other related consideration up to $75,000,000 annually and to approximately 6.8% for net revenues and other related consideration in excess of $75,000,000 on an annual basis. The Company will forgive up to $5,000,000 of the remaining $15,000,000 of Future Offsets upon the earlier of the approval of ILUVIEN for posterior uveitis in any EU country or January 1, 2020, unless certain conditions under the New Collaboration Agreement are not met. If the amounts recoverable by the Company associated with the Future Offsets are less than $5,000,000 at that time, the Company will pay EyePoint the difference in cash. The Company valued the transaction by utilizing a present value analysis at approximately $2,851,000 . Possible Reversion of the Company ’ s License Rights to EyePoint The Company’s license rights to EyePoint’s proprietary delivery device could revert to EyePoint if the Company were to: (i) fail twice to cure its breach of an obligation to make certain payments to EyePoint following receipt of written notice thereof; (ii) fail to cure other breaches of material terms of the EyePoint Agreement within 30 days after notice of such breaches or such longer period (up to 90 days ) as may be reasonably necessary if the breach cannot be cured within such 30 -day period; (iii) file for protection under the bankruptcy laws, make an assignment for the benefit of creditors, appoint or suffer appointment of a receiver or trustee over its property, file a petition under any bankruptcy or insolvency act or have any such petition filed against it and such proceeding remains undismissed or unstayed for a period of more than 60 days ; or (iv) notify EyePoint in writing of its decision to abandon its license with respect to a certain product using EyePoint’s proprietary delivery device.

Loan Agreements Loan Agreements

Loan Agreements Loan Agreements	3 Months Ended
	Mar. 31, 2018
Debt Disclosure [Abstract]
Loan Agreements	LOAN AGREEMENTS Hercules Loan Agreement In April 2014, Alimera Sciences Limited (Limited), a subsidiary of the Company, entered into a loan and security agreement (Hercules Loan Agreement) with Hercules Capital, Inc. (Hercules) providing for a term loan of up to $35,000,000 . The Company amended the 2014 Loan Agreement several times. On October 20, 2016 the Company and Hercules entered into a fourth amendment to the Hercules Loan Agreement (the Fourth Loan Amendment), which provided the operative loan agreement terms during 2017. On January 5, 2018 the Company paid off its loan with Hercules. The Fourth Loan Amendment provided for interest-only payments through November 30, 2018 (the Interest-Only Period). Pursuant to the Fourth Loan Amendment, interest on the Hercules Loan Agreement accrued at a floating per annum rate equal the greater of (i) 11.0% and (ii) the sum of (A) 11.0% plus (B) the prime rate as reported in The Wall Street Journal, or if not reported, the prime rate most recently reported in The Wall Street Journal, minus 3.5% . In addition to the interest described in the preceding sentence, the principal balance of the Hercules Loan Agreement bore “payment-in kind” interest at the rate of 1.0% (PIK Interest), which PIK Interest was added to the outstanding principal balance of the Hercules Loan Agreement. The interest rate on the Hercules Loan Agreement was 12.0% as of December 31, 2017. Under the Hercules Loan Agreement as amended by the Fourth Loan Amendment, any principal prepayment of the Hercules loan triggered a prepayment penalty equal to (a) 3.0% of the principal amount being prepaid if the prepayment occurred before October 20, 2017; (b) 2.0% of the principal amount being prepaid if the prepayment occurred after October 20, 2017 but before October 20, 2018; and (c) 1.0% of the principal amount being prepaid if the prepayment occurred at any time thereafter. Prior to entering into the Fourth Loan Agreement, the Company was already obligated to pay an end of term payment of $1,400,000 , which was paid when the Company paid off the loan with Hercules on January 5, 2018. 2014 Warrant In connection with Limited entering into the 2014 Loan Agreement, the Company issued a warrant to Hercules to purchase up to 285,016 shares of the Company’s common stock at an exercise price of $6.14 per share (the 2014 Warrant). The Company amended the 2014 Warrant a number of times to increase the number of shares issuable upon exercise to 1,258,993 and decrease the exercise price to $1.39 per share. The right to exercise this warrant expires on November 2, 2020. 2016 Warrant In connection with Limited entering into the Fourth Loan Amendment, the Company agreed to issue a new warrant to Hercules (the 2016 Warrant) to purchase up to 458,716 shares of the Company’s common stock at an exercise price of $1.09 per share. The right to exercise this warrant expires on October 20, 2021. Solar Capital Loan Agreement On January 5, 2018, the Company entered into a $40,000,000 Loan and Security Agreement (2018 Loan Agreement) with Solar Capital, as Collateral Agent (Agent), and the parties signing the 2018 Loan Agreement from time to time as Lenders, including Solar Capital in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”). Under the 2018 Loan Agreement, the Company borrowed the entire $40,000,000 as a term loan that matures on July 1, 2022. The Company used the proceeds of the term loan to extinguish the Hercules Loan Agreement and expenses. The Company used the remaining loan proceeds to provide additional working capital for general corporate purposes. Interest on the 2018 Loan Agreement is payable at one-month LIBOR plus 7.65% per annum. The 2018 Loan Agreement provides for interest-only payments for the first 30 months ending on July 1, 2020, followed by 24 months of payments of principal and interest. If the Company meets certain revenue thresholds and no event of default has occurred, the Company can extend the interest-only period an additional 6 months ending on January 1, 2021, followed by 18 months of payments of principal and interest. As of March 31, 2018, the interest rate on the 2018 Loan Agreement was approximately 9.3% . As part of the fees and expenses incurred in conjunction with the 2018 Loan Agreement discussed above, the Company paid Solar Capital a $400,000 fee at closing. The Company is obligated to pay a $1,800,000 fee upon repayment of the term loan in full ( $2,000,000 if the interest-only period has been extended to 36 months). The Company may elect to prepay the outstanding principal balance of the 2018 Loan Agreement in increments of $10,000,000 or more. The Company must pay a prepayment premium upon any prepayment of the 2018 Loan Agreement before its maturity date, whether by mandatory or voluntary prepayment, acceleration or otherwise, equal to: a. 2.00% of the principal amount prepaid for a prepayment made on or after January 5, 2018 through and including January 5, 2019; b. 1.00% of the principal amount prepaid for a prepayment made after January 5, 2019 through and including January 5, 2020; and c. 0.50% of the principal amount prepaid for a prepayment made after January 5, 2020 and greater than 30 days before the maturity date. The Company is also obligated to pay additional fees under the Exit Fee Agreement (Exit Fee Agreement) dated as of January 5, 2018 by and among the Company, Solar Capital as Agent, and the Lenders. The Exit Fee Agreement survives the termination of the 2018 Loan Agreement and has a term of 10 years. The Company is obligated to pay up to, but no more than, $2,000,000 in fees under the Exit Fee Agreement. Specifically, the Company is obligated to pay an exit fee of $2,000,000 upon a “change in control” (as defined in the Exit Fee Agreement). To the extent that Alimera has not already paid the $2,000,000 fee, the Company is also obligated to pay a fee of $1,000,000 on achieving each of the following milestones: a. first, if the Company achieves revenues of $80,000,000 or more from the sale of its ILUVIEN product in the ordinary course of business to third party customers, measured on a trailing 12-month basis during the term of the agreement, tested at the end of each month; and b. second, if the Company achieves revenues of $100,000,000 or more from the sale of its ILUVIEN product in the ordinary course of business to third party customers, measured in the same manner. The Company agreed, for itself and its subsidiaries, to customary affirmative and negative covenants and events of default in connection with the 2018 Loan Agreement. The occurrence of an event of default could result in the acceleration of the Company’s obligations under the 2018 Loan Agreement and an increase to the applicable interest rate, and would permit Solar Capital to exercise remedies with respect to the collateral under the 2018 Loan Agreement. While certain covenants are in effect from the date of the agreement, the financial covenants that require a testing of the Company’s GAAP revenues are effective as of June 30, 2018. On this date, and in subsequent quarterly periods, the revenues will be tested utilizing a trailing six-month formula to determine if the Company is in compliance. The Company’s obligations to Agent and the Lenders are secured by a first priority security interest in substantially all of the assets, excluding intellectual property, of the Company and its wholly owned subsidiary, Alimera Sciences (DE), LLC (Alimera DE), which is a guarantor of the loan, provided that only 65% of the voting interests in AS C.V., a Dutch subsidiary owned by the Company and Alimera DE, are pledged to the Lenders, and no assets or equity interests in the direct or indirect subsidiaries of AS C.V. are subject to the Lenders’ security interests. The Lender does, however, maintain a negative pledge on the property of the Company and all of its subsidiaries, including the Company’s intellectual property, requiring the Lender’s consent for any liens (other than typical permitted liens) on, or the sale of, such property. Extinguishment of Debt In accordance with the guidance in ASC 470-50, Debt , the Company accounted for the extinguishment of the Hercules Loan Amendment as an extinguishment and recognized a loss on early extinguishment of debt of approximately $1,766,000 within the condensed consolidated statement of operations for the three months ended March 31, 2018. The loss on early extinguishment consisted primarily of the early termination fee paid to Hercules and unamortized debt discounts including the remaining portion of warrant values and debt issuance costs. Fair Value of Debt The weighted average interest rates of the Company’s notes payable approximate the rate at which the Company could obtain alternative financing. Therefore, the carrying amount of the notes approximated their fair value at March 31, 2018 and December 31, 2017.

Loss Per Share (EPS)

Loss Per Share (EPS)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Loss Per Share (EPS)	LOSS PER SHARE (EPS) Basic EPS is calculated in accordance with ASC 260, Earnings per Share , by dividing net income or loss attributable to common stockholders by the weighted average common stock outstanding. Diluted EPS is calculated in accordance with ASC 260 by adjusting weighted average common shares outstanding for the dilutive effect of common stock options, warrants and convertible preferred stock. In periods where a net loss is recorded, no effect is given to potentially dilutive securities, since the effect would be anti-dilutive. Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Three Months Ended March 31, 2018 2017 Series A convertible preferred stock 9,022,556 9,022,556 Series B convertible preferred stock 8,416,251 8,416,251 Series A convertible preferred stock warrants — 4,511,279 Common stock warrants 1,795,663 1,795,663 Stock options 12,343,820 11,696,269 Restricted stock units 1,039,370 815,700 Total 32,617,660 36,257,718

Preferred Stock

Preferred Stock	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Preferred Stock	PREFERRED STOCK Series A Convertible Preferred Stock On October 2, 2012, the Company closed its preferred stock financing in which it sold units consisting of 1,000,000 shares of Series A Convertible Preferred Stock and warrants to purchase 300,000 shares of Series A Convertible Preferred Stock for gross proceeds of $40,000,000 , prior to the payment of approximately $560,000 of related issuance costs. The powers, preferences and rights of the Series A Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware on October 1, 2012. Each share of Series A Convertible Preferred Stock, including any shares of Series A Convertible Preferred Stock issued upon exercise of the warrants, is convertible into shares of the Company’s common stock at any time at the option of the holder at the rate equal to $40.00 divided by $2.66 (Conversion Price). The initial Conversion Price was subject to adjustment based on certain customary price based anti-dilution adjustments. These adjustment features lapsed in September 2014. Each share of Series A Convertible Preferred Stock shall automatically be converted into shares of common stock at the then-effective Conversion Price upon the occurrence of the later to occur of both (i) the Company receives and publicly announces the approval by the FDA of the Company’s New Drug Application (NDA) for ILUVIEN and (ii) the date on which the Company consummates an equity financing transaction pursuant to which the Company sells to one or more third party investors either (a) shares of common stock or (b) other equity securities that are convertible into shares of common stock and that have rights, preference or privileges, senior to or on a parity with, the Series A Convertible Preferred Stock, in each case having an as-converted per share of common stock price of not less than $10.00 and that results in total gross proceeds to the Company of at least $30,000,000 . The rights and preferences of Series A Convertible Preferred Stock also place limitations on the Company’s ability to declare or pay any dividend or distribution on any shares of capital stock. Each unit sold in the preferred stock financing included a warrant to purchase 0.30 shares of Series A Convertible Preferred Stock at an exercise price equal to $44.00 per share. At the election of the holder of a warrant, the warrant could have been exercised for the number of shares of common stock then issuable upon conversion of the Series A Convertible Preferred Stock that would otherwise be issued upon such exercise at the then-effective Conversion Price. These warrants were considered derivative instruments because the agreements provided for settlement in Series A Convertible Preferred Stock shares or common stock shares at the option of the holder, an adjustment to the warrant exercise price for common shares at some point in the future and contain anti-dilution provisions whereby the number of shares for which the warrants are exercisable and/or the exercise price of the warrants was subject to change in the event of certain issuances of stock at prices below the then-effective exercise price of the warrants. Therefore the warrants were recorded as a liability at issuance. The warrant anti-dilution provisions lapsed in September 2014. During the three months ended March 31, 2017, the Company recorded a gain of $167,000 as a result of the change in fair value of the warrants. The rights to exercise these warrants expired on October 1, 2017. In 2014, 6,015,037 shares of common stock were issued pursuant to the conversion of 400,000 shares of Series A Convertible Preferred Stock. As of March 31, 2018, there were 600,000 shares of Series A Convertible Preferred Stock issued and outstanding. Series B Convertible Preferred Stock On December 12, 2014, the Company closed a preferred stock financing in which it sold 8,291.873 shares of Series B Convertible Preferred Stock for a purchase price of $6,030 per share, or an aggregate purchase price of $50,000,000 , prior to the payment of approximately $432,000 of related issuance costs. The Company issued an additional 124.378 shares of Series B Convertible Preferred Stock as a subscription premium to the purchasers. The powers, preferences and rights of the Series B Convertible Preferred Stock are set forth in the certificate of designation filed by the Company with the Secretary of State of the State of Delaware. Each share of Series B Convertible Preferred Stock is convertible into 1,000 shares of the Company’s common stock at any time at the option of the holder, provided that the holder will be prohibited from converting Series B Convertible Preferred Stock into shares of the Company’s common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.98% of the total number of shares of the Company’s common stock then issued and outstanding. The Series B Convertible Preferred Stock ranks junior to the Company’s existing Series A Convertible Preferred Stock and senior to the Company’s common stock, with respect to rights upon liquidation. The Series B Convertible Preferred Stock ranks junior to all existing and future indebtedness. Except as otherwise required by law (or with respect to approval of certain actions), the Series B Convertible Preferred Stock do not have voting rights. The Series B Convertible Preferred Stock is not redeemable at the option of the holder. The Series B Convertible Preferred Stock is not subject to any price-based or other anti-dilution protections and does not provide for any accruing dividends. The Company determined that the conversion option of the Series B Convertible Preferred Stock represented a beneficial conversion feature, as the conversion feature had intrinsic value to the holder on the commitment date as a result of the subscription premium. Therefore, the Company recorded a beneficial conversion feature of $750,000 as an increase in additional paid in capital. Because the Series B Convertible Preferred Stock was immediately convertible into common stock at the option of the holder at issuance, the Company immediately accreted the full value of the beneficial conversion feature to the carrying value of the Series B Convertible Preferred Stock on that date.

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2018
Equity [Abstract]
Common Stock	COMMON STOCK In 2017, we sold 4,203,015 shares of our common stock at a weighted average price of $1.43 per share through our at-the-market offering that was in place with Cowen and Company, LLC (Cowen), for total gross proceeds of approximately $6,000,000 , reduced by approximately $183,000 of related commissions, issuance costs and placement agent fees. We used the net proceeds from this offering for general corporate purposes and working capital. The Company’s sales agreement with Cowen to sell additional shares expired on August 13, 2017. In October 2017, we entered into a sales agreement with H.C. Wainwright & Co., LLC (HCW) to offer shares of our common stock from time to time through HCW, as our sales agent, for the offer and sale of the shares up to an aggregate offering price of $25,000,000 . We have no obligation to sell shares under this sales agreement with HCW and we currently do not have plans to sell shares under this agreement. The Sales Agreement provides that HCW will be entitled to compensation for its services in an amount up to 3.0% of gross proceeds from the sale of Placement Shares, and also provided HCW with customary indemnification rights.

Stock Incentive Plans

Stock Incentive Plans	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock Incentive Plans	STOCK INCENTIVE PLANS Stock Option Plans During the three months ended March 31, 2018 and 2017, the Company recorded compensation expense related to stock options of approximately $866,000 and $972,000 , respectively. As of March 31, 2018, the total unrecognized compensation cost related to non-vested stock options granted was $5,332,000 and is expected to be recognized over a weighted average period of 2.25 years . The following table presents a summary of stock option activity for the three months ended March 31, 2018 and 2017: Three Months Ended March 31, 2018 2017 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options outstanding at beginning of period 11,595,510 $ 2.90 10,804,412 $ 3.22 Grants 1,233,000 1.16 1,312,500 1.19 Forfeitures (483,127 ) 2.34 (420,643 ) 2.79 Exercises (1,563 ) 1.06 — — Options outstanding at period end 12,343,820 2.75 11,696,269 3.00 Options exercisable at period end 8,168,883 3.24 7,527,392 3.28 Weighted average per share fair value of options granted during the period $ 0.78 $ 0.92 The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of March 31, 2018 : Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 12,343,820 $ 2.75 6.84 years $ — Exercisable 8,168,883 3.24 5.81 years — Outstanding, vested and expected to vest 11,780,737 2.81 6.74 years — The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of December 31, 2017 : Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 11,595,510 $ 2.90 6.60 years $ — Exercisable 8,085,064 3.25 5.68 years — Outstanding, vested and expected to vest 11,161,477 2.94 6.51 years — As of March 31, 2018, the Company was authorized to grant options to purchase up to an additional 1,275,715 shares under the 2010 Equity Incentive Plan, taking into account the annual increase in the number of shares available for issuance under the Company’s 2010 Equity Incentive Plan and the options and restricted stock units (RSUs) granted during the three months ended March 31, 2018. Employee Stock Purchase Plan During the three months ended March 31, 2018 and 2017, the Company recorded compensation expense related to its employee stock purchase plan of approximately $10,000 and $13,000 , respectively. Restricted Stock Units In January 2018, the Company granted 1,061,170 RSUs to its employees in lieu of a cash bonus program for 2018. As of March 31, 2018, 1,039,370 RSUs were outstanding. During the three months ended March 31, 2018, the Company recorded compensation expense of $331,000 related to outstanding and vested RSUs. In January 2017, the Company granted 873,900 RSUs to its employees in lieu of a cash bonus program for 2017, of which 839,285 RSUs vested and converted to common shares in January 2018. During the three months ended March 31, 2017, the Company recorded compensation expense related to these RSUs of $182,000 .

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2018
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES In accordance with ASC 740, Income Taxes, the Company recognizes deferred tax assets and liabilities for temporary differences between the financial reporting basis and the tax basis of its assets and liabilities at the enacted tax rates in effect for the year in which the differences are expected to reverse. The Company records a valuation allowance against its net deferred tax asset to reduce the net carrying value to an amount that is more likely than not to be realized. At the end of each interim period, the Company makes its best estimate of the effective tax rate expected to be applicable for the full fiscal year. This estimate reflects, among other items, the Company’s best estimate of operating results and foreign currency exchange rates. The Company’s quarterly income tax rate may differ from its estimated annual effective tax rate because accounting standards require the Company to exclude the actual results of certain entities expected to generate a pretax loss when applying the estimated annual effective tax rate to the Company’s consolidated pretax results in interim periods. In estimating the annual effective tax rate, the Company does not include the estimated impact of unusual and/or infrequent items, including the reversal of valuation allowances, which may cause significant variations in the customary relationship between income tax expense (benefit) and pretax income (loss) in quarterly periods. The income tax expense (benefit) for such unusual and/or infrequent items is recorded in the quarterly period such items are incurred. The Company’s income tax expense and resulting effective tax rate are based upon the respective estimated annual effective tax rates applicable for the respective periods adjusted for the effects of items required to be treated as discrete to the period, including changes in tax laws, changes in estimated exposures for uncertain tax positions and other items. The Company’s effective tax rate for the three months ended March 31, 2018 properly excluded tax benefits associated with year-to-date pre-tax losses generated in the U.S. and the Netherlands. Income tax positions are considered for uncertainty in accordance with ASC 740-10. The Company has recorded unrecognized tax benefits related to research and development tax credits. In accordance with ASC 740-10, such attributes are reduced to the amount that is expected to be recognized in the future. The Company has not accrued interest or penalties as no research and development credits have been utilized due to significant net operating losses (NOLs) available. The Company does not expect any decreases to the unrecognized tax benefits within the next twelve months due to any lapses in statute of limitations. Tax years remain subject to examination at the U.S. federal level between 2010 and 2016, and subject to examinations at various state levels between 2005 and 2016. The statute of limitations on these years will close when the NOLs expire or when the statute closes on the years in which the NOLs are utilized. Tax years since 2012 remain subject to examination in the United Kingdom and the Netherlands. Tax years since 2013 remain subject to examination in Germany. Significant management judgment is involved in determining the provision for income taxes, deferred tax assets and liabilities and any valuation allowance recorded against net deferred tax assets. Due to uncertainties with respect to the realization of deferred tax assets due to the history of operating losses, a valuation allowance has been established against the net deferred tax asset balance in the U.S. and the Netherlands. The valuation allowance is based on management’s estimates of taxable income in the jurisdictions in which the Company operates and the period over which deferred tax assets will be recoverable. In the event that actual results differ from these estimates or the Company adjusts these estimates in future periods, a change in the valuation allowance may be needed, which could materially impact the Company’s financial position and results of operations. At December 31, 2017, the Company had federal NOL carry-forwards of approximately $121,413,000 and state NOL carry-forwards of approximately $161,753,000 available to reduce future taxable income. The Company’s federal NOL carry-forwards remain fully reserved as of March 31, 2018. If not utilized, the federal NOL carry-forwards will expire at various dates between 2029 and 2037 and the state NOL carry-forwards will expire at various dates between 2020 and 2037. Sections 382 and 383 of the Internal Revenue Code (IRC) limit the annual use of NOL carry-forwards and tax credit carry-forwards, respectively, following an ownership change. NOL carry-forwards may be subject to annual limitations under IRC Section 382 (Section 382) (or comparable provisions of state law) in the event that certain changes in ownership were to occur. The Company periodically evaluates its NOL carry-forwards and whether certain changes in ownership have occurred that would limit the Company’s ability to utilize a portion of its NOL carry-forwards. If it is determined that significant ownership changes have occurred since the Company generated its NOL carry-forwards, it may be subject to annual limitations on the use of these NOL carry-forwards under Section 382 (or comparable provisions of state law). The Company determined that a Section 382 change in ownership occurred in late 2015. As a result of this change in ownership, the Company estimated that approximately $18.6 million of the Company’s federal NOLs and approximately $382,000 of federal tax credits generated prior to the change in ownership will not be utilized in the future. The Company is currently in the process of refining and finalizing these calculations, and upon finalization, will determine if a write-off is necessary. The reduction to the Company’s NOL deferred tax asset due to the annual Section 382 limitation and the NOL carryforward period would result in an offsetting reduction in valuation allowance recorded against the NOL deferred tax asset. As of December 31, 2017, the Company had cumulative book losses in foreign subsidiaries of $113,278,000 . The Company has not recorded a deferred tax asset for the excess of tax over book basis in the stock of its foreign subsidiaries. The Company anticipates that its foreign subsidiaries will be profitable and have earnings in the future. Once the foreign subsidiaries do have earnings, the Company intends to indefinitely reinvest in its foreign subsidiaries all undistributed earnings of and original investments in such subsidiaries. As a result, the Company has not recorded a deferred tax liability related to excess of book over tax basis in the stock of its foreign subsidiaries in accordance with ASC 740-30-25. On December 22, 2017, the U.S. enacted the Tax Cuts and Jobs Act (the “Act”) which made widespread changes to the Internal Revenue Code. The Act, among other things, reduced the U.S. federal corporate tax rate from 35% to 21% , requires companies to pay a transition tax on earnings of certain foreign subsidiaries that were previously not subject to U.S. tax and creates new income taxes on certain foreign sourced earnings. The Company has made reasonable estimates related to (1) the remeasurement of U.S. deferred tax balances for the reduction in the tax rate, (2) the liability for the transition tax and (3) the taxes accrued relating to the change in permanent reinvestment assertion for unremitted earnings of certain foreign subsidiaries. For the quarter ended March 31, 2018, the Company has not made any adjustments to the estimated amounts recorded as of December 31, 2017.

Segment Information

Segment Information	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION During the three months ended March 31, 2018 and 2017, two customers within the U.S. segment that are large pharmaceutical distributors accounted for 71% and 67% , respectively, of the Company’s consolidated revenues. These two customers within the U.S. segment accounted for approximately 81% of the Company’s consolidated accounts receivable at both March 31, 2018 and at December 31, 2017. The Company’s chief operating decision maker is the Chief Executive Officer (CEO). While the CEO is apprised of a variety of financial metrics and information, the business is principally managed and organized based upon geographic and regulatory environment. Each segment is separately managed and is evaluated primarily upon segment loss from operations. Non-cash items including stock-based compensation expense and depreciation and amortization are categorized as Other within the table below. The following table presents a summary of the Company’s reporting segments for the three months ended March 31, 2018 and 2017: Three Months Ended Three Months Ended U.S. International Other Consolidated U.S. International Other Consolidated (In thousands) NET REVENUE $ 6,977 $ 2,825 $ — $ 9,802 $ 4,445 $ 2,173 $ — $ 6,618 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (885 ) (391 ) — (1,276 ) (448 ) (139 ) — (587 ) GROSS PROFIT 6,092 2,434 — 8,526 3,997 2,034 — 6,031 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 1,640 950 232 2,822 1,158 741 211 2,110 GENERAL AND ADMINISTRATIVE EXPENSES 2,293 907 655 3,855 1,705 918 641 3,264 SALES AND MARKETING EXPENSES 4,371 1,278 320 5,969 4,045 1,143 314 5,502 DEPRECIATION AND AMORTIZATION — — 649 649 — — 666 666 OPERATING EXPENSES 8,304 3,135 1,856 13,295 6,908 2,802 1,832 11,542 SEGMENT LOSS FROM OPERATIONS (2,212 ) (701 ) (1,856 ) (4,769 ) (2,911 ) (768 ) (1,832 ) (5,511 ) OTHER INCOME AND EXPENSES, NET — — (2,915 ) (2,915 ) — — (1,198 ) (1,198 ) NET LOSS BEFORE TAXES $ (7,684 ) $ (6,709 )

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy	BASIS OF PRESENTATION The Company has prepared the accompanying unaudited interim condensed consolidated financial statements and notes thereto (Interim Financial Statements) in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for interim financial information, the instructions to Form 10-Q and Article 10-01 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and disclosures required by U.S. GAAP for complete financial statements. In the opinion of the Company’s management, the accompanying interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying interim financial statements and related notes should be read in conjunction with the Company’s audited financial statements for the year ended December 31, 2017 and related notes included in the Company’s Annual Report on Form 10-K, which was filed with the SEC on March 2, 2018. The financial results for any interim period are not necessarily indicative of the expected financial results for the full year.
New Accounting Pronouncements	Recent Accounting Pronouncements From time to time, the Financial Accounting Standards Board (FASB) or other standard setting bodies issue new accounting pronouncements that we adopt as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued standards that are not yet effective will not have a material impact on our financial position or results of operations upon adoption. Adoption of New Accounting Standards In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (Topic 606) , which amends the guidance for the recognition of revenue from contracts with customers to transfer goods and services. The FASB has subsequently issued an additional, clarifying ASU to address issues arising from implementation of the new revenue recognition standard. The new revenue recognition standard became effective for interim and annual periods beginning on January 1, 2018. The new standard is required to be adopted using either a full-retrospective or a modified-retrospective approach. The Company adopted the new revenue guidance on January 1, 2018 using the modified-retrospective approach. The Company elected the practical expedient to apply the new revenue standard only to contracts that were not completed as of January 1, 2018. The most significant impact of the new revenue standard relates to the accounting for the Company’s variable consideration and consideration payable to customers, specifically dealing with costs paid to its distributors. The new revenue standard requires the Company to classify consideration payable to customers as cost of goods sold, excluding depreciation and amortization, which consideration was previously classified as a discount to net revenue. Adoption did not have a material impact on the Company’s financial statements on an ongoing basis. See Note 4 for expanded disclosures. In August 2016, the FASB issued ASU 2016-15, Classification of Certain Cash Receipts and Cash Payments (Topic 230) . ASU 2016-15 is intended to add or clarify guidance on the classification of certain cash receipts and payments in the statement of cash flows and to eliminate the diversity in practice related to such classifications. The standard is effective for annual reporting periods beginning after December 15, 2017, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230) - Restricted Cash . ASU 2016-18 requires a statement of cash flows to explain the change during the period in the total of cash, cash equivalents and amounts generally described as restricted cash or restricted cash equivalents. Amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. The standard is effective for interim and annual reporting periods beginning after December 15, 2017, with early adoption permitted. The adoption of this guidance did not have a material impact on the Company’s financial statements. The Company’s condensed consolidated statement of cash flows for the three months ended March 31, 2017 has been reclassified for this ASU. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope Modification Accounting . The new standard clarifies when changes to the terms or conditions of a share-based payment award must be accounted for as modifications. This standard became effective January 1, 2018. The adoption of this guidance did not have a material impact on the Company’s financial statements. Accounting Standards Issued but Not Yet Effective In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) . This standard requires all leases with durations greater than twelve months to be recognized on the balance sheet and is effective for interim and annual reporting periods beginning after December 15, 2018, although early adoption is permitted. The primary effect of adoption will be the requirement to record right-of-use assets and corresponding lease obligations for current operating leases. In addition, the standard will require that we update our systems, processes and controls we use to track, record and account for our lease portfolio. The Company is currently in the process of evaluating the impact of the adoption on the Company’s financial statements. In February 2018, the FASB issued ASU 2018-02, Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income , to allow reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. Upon adoption of the ASU, entities will be required to describe the accounting policy for releasing income tax effects from accumulated other comprehensive income. The standard is required to be adopted for periods beginning after December 15, 2018, with early adoption available. The Company is currently in the process of evaluating the impact of the adoption on the Company’s financial statements.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	3 Months Ended
	Mar. 31, 2018
Revenue from Contract with Customer [Abstract]
Schedule of New Accounting Pronouncements and Changes in Accounting Principles	The income statement reclassifications that occurred under the new guidance for the three months ended March 31, 2018 are summarized as follows: Three Months Ended March 31, 2018 Under previous revenue recognition guidance Reclassification As reported (in thousands) NET REVENUE $ 9,630 $ 172 $ 9,802 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (1,104 ) (172 ) (1,276 ) GROSS PROFIT $ 8,526 $ — $ 8,526

Inventory (Tables)

Inventory (Tables)	3 Months Ended
	Mar. 31, 2018
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consisted of the following: March 31, 2018 December 31, 2017 (In thousands) Component parts (1) $ 371 $ 404 Work-in-process (2) 290 587 Finished goods 563 517 Total inventory $ 1,224 $ 1,508 (1) Component parts inventory consists of manufactured components of the ILUVIEN applicator. (2) Work-in-process primarily consists of completed units of ILUVIEN that are undergoing, but have not completed, quality assurance testing or stability testing as required by regulatory authorities in Europe and the U.S.

Intangible Asset (Tables)

Intangible Asset (Tables)	3 Months Ended
	Mar. 31, 2018
Intangible Assets, Net (Excluding Goodwill) [Abstract]
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	The estimated future amortization expense as of March 31, 2018 for the remaining periods in the next five years and thereafter is as follows: Years Ending December 31 (In thousands) 2018 $ 1,462 2019 1,940 2020 1,946 2021 1,940 2022 1,940 Thereafter 8,957 Total $ 18,185

Accrued Expenses (Tables)

Accrued Expenses (Tables)	3 Months Ended
	Mar. 31, 2018
Payables and Accruals [Abstract]
Summary of Accrued Expenses	Accrued expenses consisted of the following: March 31, 2018 December 31, 2017 (In thousands) Accrued clinical investigator expenses $ 661 $ 696 Accrued compensation expenses 506 511 Accrued rebate, chargeback and other revenue reserves 464 305 Accrued End of Term Payment (see Note 10) — 1,400 Other accrued expenses 649 670 Total accrued expenses $ 2,280 $ 3,582

Loss Per Share (EPS) (Tables)

Loss Per Share (EPS) (Tables)	3 Months Ended
	Mar. 31, 2018
Earnings Per Share [Abstract]
Schedule of antidilutive securities excluded from computation of earnings per share	Common stock equivalent securities that would potentially dilute basic EPS in the future, but were not included in the computation of diluted EPS because to do so would have been anti-dilutive, were as follows: Three Months Ended March 31, 2018 2017 Series A convertible preferred stock 9,022,556 9,022,556 Series B convertible preferred stock 8,416,251 8,416,251 Series A convertible preferred stock warrants — 4,511,279 Common stock warrants 1,795,663 1,795,663 Stock options 12,343,820 11,696,269 Restricted stock units 1,039,370 815,700 Total 32,617,660 36,257,718

Stock Incentive Plans (Tables)

Stock Incentive Plans (Tables)	3 Months Ended
	Mar. 31, 2018
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of stock option transactions	The following table presents a summary of stock option activity for the three months ended March 31, 2018 and 2017: Three Months Ended March 31, 2018 2017 Options Weighted Average Exercise Price Options Weighted Average Exercise Price Options outstanding at beginning of period 11,595,510 $ 2.90 10,804,412 $ 3.22 Grants 1,233,000 1.16 1,312,500 1.19 Forfeitures (483,127 ) 2.34 (420,643 ) 2.79 Exercises (1,563 ) 1.06 — — Options outstanding at period end 12,343,820 2.75 11,696,269 3.00 Options exercisable at period end 8,168,883 3.24 7,527,392 3.28 Weighted average per share fair value of options granted during the period $ 0.78 $ 0.92
Summary of additional stock option transactions	The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of March 31, 2018 : Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 12,343,820 $ 2.75 6.84 years $ — Exercisable 8,168,883 3.24 5.81 years — Outstanding, vested and expected to vest 11,780,737 2.81 6.74 years — The following table provides additional information related to outstanding stock options, exercisable stock options and stock options expected to vest as of December 31, 2017 : Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Term Aggregate Intrinsic Value (In thousands) Outstanding 11,595,510 $ 2.90 6.60 years $ — Exercisable 8,085,064 3.25 5.68 years — Outstanding, vested and expected to vest 11,161,477 2.94 6.51 years —

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended
	Mar. 31, 2018
Segment Reporting [Abstract]
Schedule of Reporting Segments	The following table presents a summary of the Company’s reporting segments for the three months ended March 31, 2018 and 2017: Three Months Ended Three Months Ended U.S. International Other Consolidated U.S. International Other Consolidated (In thousands) NET REVENUE $ 6,977 $ 2,825 $ — $ 9,802 $ 4,445 $ 2,173 $ — $ 6,618 COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION (885 ) (391 ) — (1,276 ) (448 ) (139 ) — (587 ) GROSS PROFIT 6,092 2,434 — 8,526 3,997 2,034 — 6,031 RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES 1,640 950 232 2,822 1,158 741 211 2,110 GENERAL AND ADMINISTRATIVE EXPENSES 2,293 907 655 3,855 1,705 918 641 3,264 SALES AND MARKETING EXPENSES 4,371 1,278 320 5,969 4,045 1,143 314 5,502 DEPRECIATION AND AMORTIZATION — — 649 649 — — 666 666 OPERATING EXPENSES 8,304 3,135 1,856 13,295 6,908 2,802 1,832 11,542 SEGMENT LOSS FROM OPERATIONS (2,212 ) (701 ) (1,856 ) (4,769 ) (2,911 ) (768 ) (1,832 ) (5,511 ) OTHER INCOME AND EXPENSES, NET — — (2,915 ) (2,915 ) — — (1,198 ) (1,198 ) NET LOSS BEFORE TAXES $ (7,684 ) $ (6,709 )

Nature of Operations (Detail)

Nature of Operations (Detail) - ILUVIEN	3 Months Ended
	Mar. 31, 2018Patient
Nature Of Operations [Line Items]
Post-authorization open study period (in years)	5 years
Planned drug study, number of patients	800
Number of patients	562

Summary of Significant Accoun32

Summary of Significant Accounting Policies - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Accounting Policies [Abstract]
Research and development expense	$ 104,000	$ 350,000

Revenue Recognition (Details)

Revenue Recognition (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
NET REVENUE	$ 9,802	$ 6,618
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(1,276)	(587)
GROSS PROFIT	8,526	$ 6,031
Under previous revenue recognition guidance [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
NET REVENUE	9,630
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(1,104)
GROSS PROFIT	8,526
Accounting Standards Update 2014-09 [Member] | Reclassification [Member]
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
NET REVENUE	172
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(172)
GROSS PROFIT	$ 0

Going Concern (Detail)

Going Concern (Detail) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Accumulated deficit	$ (406,758,000)	$ (399,075,000)
Cash and cash equivalents	20,253,000	$ 24,067,000
Maximum value of common stock to be sold	25,000,000
2018 Loan Agreement | Solar Capital
Debt Instrument [Line Items]
Debt instrument, face amount	$ 40,000,000

Inventory (Detail)

Inventory (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Inventory
Component parts	$ 371	$ 404
Work-in-process	290	587
Finished goods	563	517
Total inventory	$ 1,224	$ 1,508

Intangible Asset - Narrative (D

Intangible Asset - Narrative (Details) - USD ($)	1 Months Ended	3 Months Ended
	Oct. 31, 2014	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Finite-Lived Intangible Assets [Line Items]
Net intangible assets		$ 18,185,000		$ 18,664,000
License
Finite-Lived Intangible Assets [Line Items]
Gross intangible assets		$ 25,000,000
Useful life (in years)		13 years
Amortization of intangible assets		$ 478,000,000	$ 478,000
Net intangible assets		$ 18,185,000		$ 18,664,000
pSivida
Finite-Lived Intangible Assets [Line Items]
Milestone payment after the first product approved by the FDA	$ 25,000,000

Intangible Asset - Future Amort

Intangible Asset - Future Amortization (Details) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Total	$ 18,185,000	$ 18,664,000
License
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
2,018	1,462,000
2,019	1,940,000
2,020	1,946,000
2,021	1,940,000
2,022	1,940,000
Thereafter	8,957,000
Total	$ 18,185,000	$ 18,664,000

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Detail) - USD ($) $ in Thousands	Mar. 31, 2018	Dec. 31, 2017
Payables and Accruals [Abstract]
Accrued clinical investigator expenses	$ 661	$ 696
Accrued compensation expenses	506	511
Accrued rebate, chargeback and other revenue reserves	464	305
Debt instrument, periodic payment terms, balloon payment to be paid	0	1,400
Other accrued expenses	649	670
Total accrued expenses	$ 2,280	$ 3,582

License Agreements (Details)

License Agreements (Details) - USD ($)	Jul. 10, 2017	Mar. 31, 2018	Sep. 30, 2017	Jun. 30, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Profit share expense		$ 197,000
Collaborative Arrangement, Co-promotion
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Share of net profits	20.00%	20.00%
Share of any lump sum milestone payments received from sub licensee of Iluvien		33.00%
Percentage of recovery of commercialization cost		20.00%
Collaborative arrangement, royalty payable on net revenue, percentage	2.00%
Collaborative arrangement, increase in royalty payable on net revenue	6.00%
Reduction in royalty on net revenues up to threshold, third year and thereafter, percentage	5.20%
Reduction in royalty on net revenues up to threshold, first two years, percentage	4.00%
Collaborative arrangement, royalty payable on net revenue over threshold, percentage	2.00%
Collaborative arrangement, royalty payable on net revenue, revenue threshold	$ 75,000,000
Collaborative arrangement, forgiveness of future offset, additional amount	$ 5,000,000
Reduction in royalty on net revenues in excess of threshold, third year and thereafter, percentage	6.80%
Reduction in royalty on net revenues in excess of threshold, first two years, percentage	5.00%
Collaborative arrangement, forgiveness of future offset	$ 10,000,000
Collaborative agreement, capped future offset amount	25,000,000
Research and development expense, non-cash			$ 2,851,000
Minimum days to require to revert license in case of breach of contract		30 days
Maximum days to require to revert license in case of breach of contract		90 days
Bankruptcy proceedings period petitions for bankruptcy filed		60 days
New Collaboration Agreement, 2017 Second Amended
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Royalty expense		$ 193,000
Royalty future offset				$ 25,000,000
Maximum | Collaborative Arrangement, Co-promotion
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Collaborative arrangement, forgiveness of future offset, additional amount	5,000,000
Recoverable amount to offset future royalty payments	$ 15,000,000

Loan Agreements (Details)

Loan Agreements (Details) - USD ($)	Jan. 05, 2018	Oct. 31, 2016	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017	Jul. 31, 2016	Apr. 30, 2014
Debt Instrument [Line Items]
NET REVENUE			$ 9,802,000	$ 6,618,000
Gain (loss) on extinguishment of debt			(1,766,000)	$ 0
Solar Capital Ltd. | Twenty Eighteen Term Loan
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity	$ 40,000,000
Debt instrument, fee amount	$ 1,800,000
Interest only payments, term	30 months
Debt instrument, interest only payments, additional term	6 months
Principal and interest payments, term	18 months
Payments for brokerage fees	$ 400,000
Debt instrument, fee amount if interest only period is extended	$ 2,000,000
Debt instrument, interest only payments, extension term	36 months
Debt instrument, incremental prepayments of outstanding balance	$ 10,000,000
Debt instrument, additional exit fee	$ 1,000,000
Debt instrument, covenant, voting interests, percentage	65.00%
Solar Capital Ltd. | Twenty Eighteen Term Loan | London Interbank Offered Rate (LIBOR)
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate	7.65%
Solar Capital Ltd. | Twenty Eighteen Term Loan | Tranche One
Debt Instrument [Line Items]
Debt instrument, principal prepayment fee percentage, first 12 months	2.00%
Solar Capital Ltd. | Twenty Eighteen Term Loan | Tranche Two
Debt Instrument [Line Items]
Debt instrument, principal prepayment fee percentage, greater than 12 months, less than 24 months	1.00%
Solar Capital Ltd. | Twenty Eighteen Term Loan | Tranche Three
Debt Instrument [Line Items]
Debt instrument, principal prepayment fee percentage, greater than 24 months	0.50%
Debt instrument, number of days before maturity date	30 days
Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | Twenty Fourteen Term Loan
Debt Instrument [Line Items]
Line of credit facility, maximum borrowing capacity							$ 35,000,000
Debt instrument, interest rate, effective percentage					12.00%
Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | Fourth Loan Amendment
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage		11.00%
Debit Instrument, Payment-in-Kind Interest Rate		1.00%
Debt instrument, prepayment fee percentage, first 12 months		3.00%
Debt instrument, prepayment fee percentage, greater than 12 months, less than 24 months		2.00%
Debt instrument, prepayment fee percentage, greater than 24 months		1.00%
Debt instrument, fee amount					$ 1,400,000
Class of warrant or right, number of securities called by warrants or rights (in shares)		458,716
Class of warrant or right, exercise price of warrants or rights (in USD per share)		$ 1.09
Gain (loss) on extinguishment of debt			$ 1,766,000
Alimera Sciences Limited (Limited) | Hercules Technology Growth Capital, Inc. | Fourth Loan Amendment | Prime Rate
Debt Instrument [Line Items]
Debt instrument, basis spread on variable rate		11.00%
Debt instrument, basis spread on variable rate, reduction		3.50%
Alimera Sciences Limited (Limited) | Solar Capital | 2018 Loan Agreement
Debt Instrument [Line Items]
Debt instrument, interest rate, stated percentage			9.30%
Alimera Sciences, Inc.(Company) | Hercules Technology Growth Capital, Inc. | Twenty Fourteen Term Loan
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares)							285,016
Class of warrant or right, exercise price of warrants or rights (in USD per share)							$ 6.14
Alimera Sciences, Inc.(Company) | Hercules Technology Growth Capital, Inc. | July 2016 Waiver
Debt Instrument [Line Items]
Class of warrant or right, number of securities called by warrants or rights (in shares)						1,258,993
Class of warrant or right, exercise price of warrants or rights (in USD per share)						$ 1.39
Exit Fee Agreement | Solar Capital Ltd. | Twenty Eighteen Term Loan
Debt Instrument [Line Items]
Debt instrument, term	10 years
Debt instrument, exit fee	$ 2,000,000
ILUVIEN | Solar Capital Ltd. | Twenty Eighteen Term Loan | Tranche One
Debt Instrument [Line Items]
NET REVENUE	80,000,000
ILUVIEN | Solar Capital Ltd. | Twenty Eighteen Term Loan | Tranche Two
Debt Instrument [Line Items]
NET REVENUE	$ 100,000,000

Loss Per Share (EPS) - AntiDilu

Loss Per Share (EPS) - AntiDilutive Securities Excluded (Detail) - shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	32,617,660	36,257,718
Series A convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	9,022,556	9,022,556
Series B convertible preferred stock
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	8,416,251	8,416,251
Series A convertible preferred stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	4,511,279
Common stock warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,795,663	1,795,663
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	12,343,820	11,696,269
Restricted stock units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (in shares)	1,039,370	815,700

Preferred Stock (Detail)

Preferred Stock (Detail) - USD ($)	Dec. 12, 2014	Oct. 02, 2012	Mar. 31, 2017	Dec. 31, 2014	Mar. 31, 2018	Dec. 31, 2017
Conversion of Stock [Line Items]
Gain (loss) on change in fair value of derivatives			$ 167,000
Series A convertible preferred stock
Conversion of Stock [Line Items]
Number of preferred stock and warrants (in shares)		1,000,000
Warrants to purchase additional shares (in shares)		300,000
Gross proceeds under securities purchase agreement		$ 40,000,000
Estimated total stock issuance cost		$ 560,000
Conversion rate of Series A Convertible Preferred Stock issued upon exercise of warrants into common stock (in dollar per share)		$ 40
Initial conversion price (in dollars per share)		2.66
Preferred stock converted to common stock per share (in dollars per share)		$ 10
Proceeds from issuance of preferred stock		$ 30,000,000
Proportion of each unit of shares (in shares)		0.30
Exercise price of warrants (in dollars per share)		$ 44
Convertible securities converted (in shares)				400,000
Preferred stock, shares issued (in shares)					600,000	600,000
Preferred stock, shares outstanding (in shares)					600,000	600,000
Common stock
Conversion of Stock [Line Items]
Common stock issued upon conversion of convertible securities (in shares)				6,015,037
Series B convertible preferred stock
Conversion of Stock [Line Items]
Preferred stock, shares issued (in shares)					8,416.251	8,416.251
Preferred stock, shares outstanding (in shares)					8,416.251	8,416.251
Issuance of stock (in shares)	8,291.873
Share purchase price of shares issued (in dollars per share)	$ 6,030
Stock issued during period	$ 50,000,000
Payment of stock issuance cost	$ 432,000
Shares issued upon conversion (in shares)	1,000
Ownership interest after conversion (percent)	9.98%
Adjustment to APIC	$ 750,000
Series B convertible preferred stock | Over-Allotment Option
Conversion of Stock [Line Items]
Issuance of stock (in shares)	124.378

Common Stock (Detail)

Common Stock (Detail) - USD ($)	1 Months Ended	12 Months Ended
	Oct. 31, 2017	Dec. 31, 2017	Mar. 31, 2018
Class of Stock [Line Items]
Maximum value of common stock to be sold			$ 25,000,000
Private placement | Common stock
Class of Stock [Line Items]
Issuance of stock (in shares)		4,203,015
Share purchase price of shares issued (in dollars per share)		$ 1.43
Proceeds from sale of common stock		$ 6,000,000
Payment of stock issuance cost		$ 183,000
Maximum value of common stock to be sold	$ 25,000,000
Stock issuance costs (in percent)	3.00%

Stock Incentive Plans - Additio

Stock Incentive Plans - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended		12 Months Ended
	Jan. 31, 2018	Jan. 31, 2017	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average contractual term			5 years 9 months 21 days		5 years 8 months 5 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 866	$ 972
Share-based compensation not yet recognized			$ 5,332
Weighted average contractual term			2 years 2 months 29 days
Equity Incentive Plan 2010 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Awards granted in period (in shares)			1,275,715
Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 10	13
Restricted stock units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense			$ 331	$ 182
Awards granted in period (in shares)	1,061,170	873,900
Restricted shares outstanding (in shares)			1,039,370
Awards vested in period (in shares)		839,285

Stock Incentive Plans - Summary

Stock Incentive Plans - Summary of Stock Option Transactions (Detail) - $ / shares	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Options
Options outstanding at beginning of period (in shares)	11,595,510	10,804,412
Grants (in shares)	1,233,000	1,312,500
Forfeitures (in shares)	(483,127)	(420,643)
Exercises (in shares)	(1,563)	0
Options outstanding at year end (in shares)	12,343,820	11,696,269
Options exercisable at year end (in shares)	8,168,883	7,527,392	8,085,064
Weighted average per share fair value of options granted during the period (in dollars per share)	$ 0.78	$ 0.92
Weighted Average Exercise Price
Options outstanding at beginning of period (in dollars per share)	2.90	3.22
Grants (in dollars per share)	1.16	1.19
Forfeitures (in dollars per share)	2.34	2.79
Exercises (in dollars per share)	1.06	0
Options outstanding at year end (in dollars per share)	2.75	3
Options exercisable at year end (in dollars per share)	$ 3.24	$ 3.28	$ 3.25

Stock Incentive Plans - Addit46

Stock Incentive Plans - Additional Stock Option Transactions (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2018	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Outstanding Stock Options
Outstanding, shares	12,343,820	11,595,510	11,696,269	10,804,412
Outstanding, weighted average exercise price (in dollars per share)	$ 2.75	$ 2.90	$ 3	$ 3.22
Outstanding, weighted average remaining contractual term	6 years 10 months 1 day	6 years 7 months 6 days
Outstanding, aggregate intrinsic value	$ 0	$ 0
Exercisable Stock Options
Exercisable, shares	8,168,883	8,085,064	7,527,392
Exercisable, weighted average exercise price (in dollars per share)	$ 3.24	$ 3.25	$ 3.28
Exercisable, weighted average remaining contractual term	5 years 9 months 21 days	5 years 8 months 5 days
Exercisable, aggregate intrinsic value	$ 0	$ 0
Exercisable and expected to vest
Outstanding, vested and expected to vest, shares	11,780,737	11,161,477
Outstanding, vested and expected to vest, weighted average exercise price (in dollars per share)	$ 2.81	$ 2.94
Outstanding, vested and expected to vest, weighted average remaining contractual term	6 years 8 months 25 days	6 years 6 months 3 days
Outstanding, vested and expected to vest, aggregate intrinsic value	$ 0	$ 0

Income Taxes (Detail)

Income Taxes (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2015	Dec. 31, 2017
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, valuation allowance			$ 18,600,000
Federal tax credits, unable to be utilized post change in ownership			$ 382,000
Cumulative book losses in foreign subsidiaries				$ 113,278,000
Income tax benefit	$ 0	$ 26,000
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards				121,413,000
State
Operating Loss Carryforwards [Line Items]
Net operating loss carry-forwards				$ 161,753,000

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018USD ($)customer	Mar. 31, 2017USD ($)customer	Dec. 31, 2017customer
Segment Reporting Information [Line Items]
Net revenue	$ 9,802	$ 6,618
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(1,276)	(587)
GROSS PROFIT	8,526	6,031
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	2,822	2,110
GENERAL AND ADMINISTRATIVE EXPENSES	3,855	3,264
SALES AND MARKETING EXPENSES	5,969	5,502
DEPRECIATION AND AMORTIZATION	649	666
OPERATING EXPENSES	13,295	11,542
SEGMENT LOSS FROM OPERATIONS	(4,769)	(5,511)
OTHER INCOME AND EXPENSES, NET	(2,915)	(1,198)
NET LOSS BEFORE TAXES	(7,684)	(6,709)
U.S.
Segment Reporting Information [Line Items]
Net revenue	6,977	4,445
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(885)	(448)
GROSS PROFIT	6,092	3,997
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	1,640	1,158
GENERAL AND ADMINISTRATIVE EXPENSES	2,293	1,705
SALES AND MARKETING EXPENSES	4,371	4,045
DEPRECIATION AND AMORTIZATION	0	0
OPERATING EXPENSES	8,304	6,908
SEGMENT LOSS FROM OPERATIONS	(2,212)	(2,911)
International
Segment Reporting Information [Line Items]
Net revenue	2,825	2,173
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	(391)	(139)
GROSS PROFIT	2,434	2,034
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	950	741
GENERAL AND ADMINISTRATIVE EXPENSES	907	918
SALES AND MARKETING EXPENSES	1,278	1,143
DEPRECIATION AND AMORTIZATION	0	0
OPERATING EXPENSES	3,135	2,802
SEGMENT LOSS FROM OPERATIONS	(701)	(768)
Other Segments
Segment Reporting Information [Line Items]
Net revenue	0	0
COST OF GOODS SOLD, EXCLUDING DEPRECIATION AND AMORTIZATION	0	0
GROSS PROFIT	0	0
RESEARCH, DEVELOPMENT AND MEDICAL AFFAIRS EXPENSES	232	211
GENERAL AND ADMINISTRATIVE EXPENSES	655	641
SALES AND MARKETING EXPENSES	320	314
DEPRECIATION AND AMORTIZATION	649	666
OPERATING EXPENSES	1,856	1,832
SEGMENT LOSS FROM OPERATIONS	(1,856)	(1,832)
OTHER INCOME AND EXPENSES, NET	$ (2,915)	$ (1,198)
Customer Concentration Risk | Revenues
Segment Reporting Information [Line Items]
Number of customers | customer	2	2
Concentration risk percentage	71.00%	67.00%
Customer Concentration Risk | Accounts Receivable
Segment Reporting Information [Line Items]
Number of customers | customer	2		2
Concentration risk percentage	81.00%		81.00%